This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Insulin and glucose in the treatment of hyperkalaemia

Authoring team

Adult dose:

  • 10u of soluble insulin (eg actrapid) with 50mls of 50% glucose (ie 25g) given over 15 minutes.

Insulin stimulates the Na+-K+ ATPase pump in skeletal muscle, cardiac muscle and liver so driving potassium into cells. Serum potassium concentration is therefore lowered. Simultaneous administration of glucose is necessary in order to prevent hypoglycaemia.

Effects should be apparent within 30-60 minutes and should last for 4-6 hours. Insulin produces only a temporary reduction in serum potassium. It does not remove K+ from the body. It may be necessary to repeat administration or continue infusion at a ratio of 3-4g of glucose to each unit of insulin. Titrate against serum potassium and glucose.

CAUTION IN DIABETIC PATIENTS.

In children an insulin infusion may be used, starting at approximately 0.05 units of insulin per kilogram body weight per hour, usually made up as 50 units of fast acting insulin in 50 ml of normal saline. Note that it is mandatory under these circumstances to also have a glucose infusion running, and to keep a very close eye on the blood sugar level.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.